BRIEF-Vertex to present mid-stage study data of experimental fibrosis drug


Oct 11 (Reuters) - Vertex Pharmaceuticals Inc :

* Data from phase 2 combination study of vx-809 and ivacaftor in people with

cystic fibrosis who have the most common genetic mutation (f508del) presented

at North American cystic fibrosis conference

* Source text* Further company coverage

((Bangalore Newsroom; +1 646 223 8780))